Dr. Flavio Salazar-Onfray
Ph.D. in Immunology
Karolinska Institute. Sweden

 
     
  Publications  
     
 
 

Mendoza-Naranjo A, Saez PJ, Johansson CC, Ramirez M, Mandakovic D, Pereda C, López MN, Kiessling R, Sáez JC, Salazar-Onfray F.
Functional gap junctions facilitate melanoma antigen transfer and cross-presentation between human dendritic cells. J Immunol. 2007 Jun 1;178(11):6949-57.

 
  
Cuchacovich M, Soto L, Edwardes M, Gutierrez M, Llanos C, Pacheco D, Sabugo F, Alamo M, Fuentealba C, Villanueva L, Gatica H, Schiattino I, Salazaro L, Catalan D, Valenzuela O, Salazar-Onfray F, Aguillon JC.
Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis.
Scand J Rheumatol. 2006 Nov-Dec;35(6):435-40.
 
 
Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A.
Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape.
 
 
Lopez MN, Pereda C, Ramirez M, Mendoza-Naranjo A, Serrano A, Ferreira A, Poblete R, Kalergis AM, Kiessling R, Salazar-Onfray F.
Melanocortin 1 receptor is expressed by uveal malignant melanoma and can be considered a new target for diagnosis and immunotherapy.
Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1219-27.
 
 
Lopez M, Aguilera R, Perez C, Mendoza-Naranjo A, Pereda C, Ramirez M, Ferrada C, Aguillon JC, Salazar-Onfray F.
The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines.
Immunobiology. 2006;211(1-2):127-36. Epub 2006 Jan 4. Review.
 
 
Gomez CR, Acuna-Castillo C, Nishimura S, Perez V, Escobar A, Salazar-Onfray F, Sabaj V, Torres C, Walter R, Sierra F.
Serum from aged F344 rats conditions the activation of young macrophages.
Mech Ageing Dev. 2006 Mar;127(3):257-63. Epub 2005 Dec 15.
 
 
Escobar A, Lopez M, Serrano A, Ramirez M, Perez C, Aguirre A, Gonzalez R, Alfaro J, Larrondo M, Fodor M, Ferrada C, Salazar-Onfray F.
Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
Clin Exp Immunol. 2005 Dec;142(3):555-68.
 
 
Lopez M, Escobar A, Alfaro J, Fodor M, Larrondo M, Ferrada C, Salazar-Onfray F.
[Advances in cellular immunotherapy for malignant melanoma]
Rev Med Chil. 2004 Sep;132(9):1115-26. Review. Spanish.
 
 
Cuchacovich M, Ferreira L, Aliste M, Soto L, Cuenca J, Cruzat A, Gatica H, Schiattino I, Perez C, Aguirre A, Salazar-Onfray F, Aguillon JC.
Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand J Rheumatol. 2004;33(4):228-32.
 
 
Kurte M, Lopez M, Aguirre A, Escobar A, Aguillon JC, Charo J, Larsen CG, Kiessling R, Salazar-Onfray F.
A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and Transporter associated with Antigen Processing 1/2 in human melanoma cells. J Immunol. 2004 Aug 1;173(3):1731-7.
 
 
Aguillon JC, Contreras J, Dotte A, Cruzat A, Catalan D, Salazar L, Molina MC, Guerrero J, Lopez M, Soto L, Salazar-Onfray F, Cuchacovich M.
[New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies]. Rev Med Chil. 2003 Dec;131(12):1445-53. Review. Spanish.
 
 
Cuenca J, Cuchacovich M, Perez C, Ferreira L, Aguirre A, Schiattino I, Soto L, Cruzat A, Salazar-Onfray F, Aguillon JC.
The -308 polymorphism in the tumour necrosis factor (TNF) gene promoter region and ex vivo lipopolysaccharide-induced TNF expression and cytotoxic activity in Chilean patients with rheumatoid arthritis. Rheumatology (Oxford). 2003 Feb;42(2):308-13.
 
 
Salazar-Onfray F, Lopez M, Lundqvist A, Aguirre A, Escobar A, Serrano A, Korenblit C, Petersson M, Chhajlani V, Larsson O, Kiessling R.
Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker. Br J Cancer. 2002 Aug 12;87(4):414-22.
 
 
Salazar-Onfray F.
Interleukin-10: a cytokine used by tumors to escape immunosurveillance. Med Oncol. 1999 Jul;16(2):86-94. Review.
 
 
Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Appella E, Sette A, Celis E, Kiessling R.
Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol. 1999 Jul 15;163(2):1037-44.
 
 
Petersson M, Charo J, Salazar-Onfray F, Noffz G, Mohaupt M, Qin Z, Klein G, Blankenstein T, Kiessling R.
Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J Immunol. 1998 Sep 1;161(5):2099-105.
 
 
Salazar-Onfray F, Nakazawa T, Chhajlani V, Petersson M, Karre K, Masucci G, Celis E, Sette A, Southwood S, Appella E, Kiessling R.
Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells.Cancer Res. 1997 Oct 1;57(19):4348-55.
 
 
Salazar-Onfray F, Charo J, Petersson M, Freland S, Noffz G, Qin Z, Blankenstein T, Ljunggren HG, Kiessling R.
Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. J Immunol. 1997 Oct 1;159(7):3195-202.
 
 
Kono K, Salazar-Onfray F, Petersson M, Hansson J, Masucci G, Wasserman K, Nakazawa T, Anderson P, Kiessling R.
Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol. 1996 Jun;26(6):1308-13.
 
 
Salazar-Onfray F, Petersson M, Franksson L, Matsuda M, Blankenstein T, Karre K, Kiessling R.
IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression. J Immunol. 1995 Jun 15;154(12):6291-8.